WSJ News Exclusive | J&J Slashes Production of Its Unpopular Covid-19 Shot

[ad_1]

After mobilizing to quickly develop and manufacture a Covid-19 vaccine, Johnson & Johnson has vastly scaled back its efforts in producing the shots as it faces slumping demand.

The New Brunswick, N.J., pharmaceutical company in recent months terminated manufacturing agreements with companies that helped produce the shot during the pandemic such as Catalent Inc. and Sanofi SA. 

[ad_2]

Source link